Therefore, our findings imply that endocytosis of TLR4 and NOX2 could be a novel therapeutic target for NAFLD, including hepatic steatosis and insulin resistance. This evidence concerns the gene TLR4 and metabolic dysfunction-associated steatotic liver disease.